A5017511449- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Cancer, Stress, Anesthesia, and Immune Response
- Radiation Therapy and Dosimetry
- Receptor Mechanisms and Signaling
- Neuropeptides and Animal Physiology
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Nitric Oxide and Endothelin Effects
- PARP inhibition in cancer therapy
- Adipose Tissue and Metabolism
- Cancer Immunotherapy and Biomarkers
- Chemical Reactions and Isotopes
- Cancer, Lipids, and Metabolism
- Ultrasound and Hyperthermia Applications
- Traumatic Brain Injury and Neurovascular Disturbances
- Monoclonal and Polyclonal Antibodies Research
- Mitochondrial Function and Pathology
- Prostate Cancer Diagnosis and Treatment
- Cardiac electrophysiology and arrhythmias
- Click Chemistry and Applications
University of Iowa
2023
University of California, Los Angeles
2020
Prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy (RNT) may increase tumor immunogenicity. We aimed at exploiting this effect by combining RNT with immunotherapy in a mouse model of prostate cancer (PC). <b>Methods:</b> C57BL/6-mice bearing syngeneic RM1-PGLS tumors were treated <sup>225</sup>Ac-PSMA617, an anti-PD-1 antibody, or both. Therapeutic efficacy was assessed volume measurements (CT), time to progression (TTP), and survival. <b>Results:</b> PSMA alone tended...
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is effective against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the underlying resistance mechanisms represents a key barrier to development more RLT. We investigate proteome and phosphoproteome in mouse model PCa identify signaling adaptations triggered by PSMA
<div>AbstractPurpose:<p>Prostate-specific membrane antigen (PSMA) targeting radioligands deliver radiation to PSMA-expressing cells. However, the relationship between PSMA levels and intralesion heterogeneity of expression, cytotoxic by radioligand therapy (RLT) is unknown. Here we investigate RLT efficacy as function levels/cell, fraction PSMA<sup>+</sup> cells in a tumor.</p>Experimental Design:<p>RM1 expressing different (PSMA<sup>−</sup>,...
Diffuse intrinsic pontine gliomas (DIPG) are an aggressive type of pediatric brain tumor with a very high mortality rate. Surgery has limited role given the tumors location. Palliative radiation therapy alleviates symptoms and prolongs survival, but median survival remains less than 1 year. There is no clear for chemotherapy in DIPGs as trials adding to palliative have failed improve compared alone. Thus, there critical need identify tissue-specific radiosensitizers clinical outcomes...
Introduction: Cardiac irradiation causes heart failure and arrhythmias. We reported that cardiac-targeted (CTI) led to cardiac dilation with increased end diastolic volume (EDV) by echocardiogram (echo) after 9 months in wild-type C57Bl6/J (WT) male (M) but not female (F) mice. Both sexes developed fibrosis evidence of lung congestion, the radiation mitigator MMS350 did protect either sex. Here, we studied effect CTI on Nitric Oxide Synthase 1 haploinsufficient (Nos +/- ) mice treated...
Introduction: We reported that a mutation in Glycerol-3-Phosphdate Dehydrogenase-1 Like (GPD1L-A280V) is linked to Brugada Syndrome (BrS). This increases acetylation and reduces surface expression of Nav1.5, inward Na+ current (INa) HEK293 cells rat neonatal cardiac myocytes. Global homozygous knockout Gpd1-l mice (Gpd1l-/-) was usually lethal, though we noted increased Nav1.5 acetylation, decreased INa, pharmacologically inducible arrhythmias Gpd1l+/- heterozygotes. Cardiac-specific...
<p>PSMA expression is heterogenous in human PC</p>
<p>Characteristics of the RM1 mouse model</p>
<p>Characterization of the PC-3 tumor model</p>
<p>PSMA expression in tumors with different fractions of PSMA-positive cells and growth untreated study 4.</p>
<p>PSMA expression in tumors with different fractions of PSMA-positive cells and growth untreated study 4.</p>
<p>PSMA expression is heterogenous in human PC</p>
<p>Absolute tumor volumes and bodyweights</p>
<p>Characteristics of the RM1 mouse model</p>
<div>AbstractPurpose:<p>Prostate-specific membrane antigen (PSMA) targeting radioligands deliver radiation to PSMA-expressing cells. However, the relationship between PSMA levels and intralesion heterogeneity of expression, cytotoxic by radioligand therapy (RLT) is unknown. Here we investigate RLT efficacy as function levels/cell, fraction PSMA<sup>+</sup> cells in a tumor.</p>Experimental Design:<p>RM1 expressing different (PSMA<sup>−</sup>,...
<p>PSMA expression in tumors with different fractions of PSMA-positive cells (study 2)</p>
<p>Absolute tumor volumes and bodyweights</p>
<p>PSMA expression in tumors with different fractions of PSMA-positive cells (study 2)</p>
<p>Characterization of the PC-3 tumor model</p>
Abstract Radioligand therapy (RLT) with prostate-specific membrane antigen (PSMA)-targeting ligands is effective in ~50% of patients advanced prostate cancer (PC). Causes for RLT failure are not well understood. The prevalent PSMA heterogeneity PC might contribute to failure. Here we investigate the relationship between efficacy and levels per cell, heterogeneity. cells expressing different (RM1-PSMA low, medium, high, or RM1-YFP that do express PSMA), a mix PSMA− PSMA+ (RM1-YFP/...
<h3>Background</h3> AMG 160 is an HLE BiTE<sup>®</sup> (half-life extended bispecific T-cell engager) that binds PSMA on prostate cancer cells and CD3 T-cells induces redirected lysis of PSMA-expressing cells. This mechanism may allow the BiTE molecule to be active in settings where other targeted or immune therapies have failed. Here, we evaluated activity mouse models advanced are resistant <sup>177</sup>Lu-PSMA-617, a PSMA-targeted radioligand therapy has emerged as promising treatment...